Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Forespi tablets

Dexa Medica

Ingredients in every tablet

Roflumilast 500 mcg

Each package contains

3 blisters of 10 tablets

Dosage form

tablet

Dosage formTablet; coated

Flavour

None

W.H.O. classification

R03D
R03D

A.T.C. Level 1

Anatomical Main group

R - Respiratory system
R03D

A.T.C. Level 2

Therapeutic subgroup

R03 - Drugs for Obstructive Airway Diseases
R03D

A.T.C. Level 3

Pharmacological subgroup

R03D - Other Systemic Drugs for Obstructive Airway Diseases in ATC

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Roflumilast is indicated as add-on therapy to long-acting bronchodilator(s) treatment for the maintenance of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations.

Dosage

18 YEARS OLD AND ABOVE
The recommended dose is 1 tablet of 500 mcg, once daily.

The tablet should be swallowed with water and taken at the same time every day. The tablet can be taken with or without food. FORESPI film-coated tablets can be taken for several weeks to achieve the desired effect.

UP TO 18 YEARS
There is no relevant use of FORESPI film-coated tablet in the pediatric population (under 18 years) in the indication of COPD.

65 YEARS OLD AND ABOVE
No dosage adjustment is necessary for elderly patients (65 years and older)

RENAL IMPAIRMENT
No dosage adjustment is necessary for patients with renal impairment.

HEPATIC IMPAIRMENT
FORESPI film-coated tablet should be used with caution in patients with mild hepatic impairment classified as Child-Pugh A. Patients with moderate or severe hepatic impairment classified as Child-Pugh B or C must not take FORESPI film-coated tablet